Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.

Oregon Public Health Division, Portland, OR 97212, USA.
The Journal of Infectious Diseases (Impact Factor: 5.78). 01/2012; 205(1):13-9. DOI: 10.1093/infdis/jir695
Source: PubMed

ABSTRACT Statins may have anti-inflammatory and immunomodulatory effects that could reduce the risk of mortality from influenza virus infections.
The Centers for Disease Control and Prevention's Emerging Infections Program conducts active surveillance for persons hospitalized with laboratory-confirmed influenza in 59 counties in 10 states. We analyzed data for hospitalized adults during the 2007-2008 influenza season to evaluate the association between receiving statins and influenza-related death.
We identified 3043 patients hospitalized with laboratory-confirmed influenza, of whom 1013 (33.3%) received statins and 151 (5.0%) died within 30 days of their influenza test. Patients who received statins were more likely to be older, male, and white; to suffer from cardiovascular, metabolic, renal, and chronic lung disease; and to have been vaccinated against influenza that season. In a multivariable logistic regression model, administration of statins prior to or during hospitalization was associated with a protective odds of death (adjusted odds ratio, 0.59 [95% confidence interval, .38-.92]) when adjusting for age; race; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration.
Statin use may be associated with reduced mortality in patients hospitalized with influenza.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The influenza virus (IV) is known to be a resistant virus with frequent mutations, causing severe respiratory diseases in the upper respiratory system. Public health concerns about clinical efficacy of all conventional drugs are ambiguous; therefore, finding additional therapeutic agents is critical to prevent and control influenza outbreaks. Influenza is associated with the induction of proinflammatory cytokines. Scientists have reported that anti-inflammatory drugs, with pleiotropic effects, reduce the burden of severe influenza diseases. Therefore, statins, which are cardioprotective drugs with anti-inflammatory and immunomodulatory effects, may help patients suffering from influenza virus (IV). This review delineates the potential use of statins as an alternative therapy in treating influenza related illness.
    BioMed Research International 01/2014; 2014(11):1-8. DOI:10.1155/2014/872370 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Bronchiectasis is a chronic respiratory condition characterised by cough, sputum production and recurrent chest infections. There are multiple aetiologies; but in up to 50% of patients, the aetiology is unknown. The treatment is largely symptomatic with regular chest physiotherapy and antibiotics for infective exacerbations. Research is being directed towards breaking the ‘vicious circle’ of bronchiectasis with therapies directed at improving mucociliary clearance, treating chronic infection and reducing inflammation in the airways.Areas covered: This review highlights the current status of bronchiectasis research, summarising reported and ongoing studies of potential therapeutic agents not yet assessed in large trials or licensed for treatment. A literature review was performed using the PubMed database and upcoming trials were sought on the website. The article is limited to studies in preclinical to Phase II clinical trials. The trials highlighted in this article offer insight into potential therapeutic agents for the future and help highlight areas in need of further targeted research.Expert opinion: There are promising new anti-infective and anti-inflammatory therapies for more advanced bronchiectasis. That being said, Phase III studies are still needed to investigate these agents further, as well as at what stage therapy should be implemented.
    Expert Opinion on Investigational Drugs 10/2014; 24(2). DOI:10.1517/13543784.2015.971153 · 5.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have reported that statin use may be associated with improved outcomes in patients with sepsis or respiratory viral infections. In the setting of allogeneic hematopoietic cell transplantation (HCT), it has been shown that donor and recipient statin use is associated with reduced risks of GVHD. We assessed in retrospective analysis whether donor or recipient statin use impacts infection risk after allogeneic HCT (n=1191). Although recipient statin use was associated with the increased incidence of Gram-negative bacteremia (adjusted hazard ratio (aHR) 2.22, (95% confidence interval (CI) 1.2-4.2), P=0.01) without affecting mortality, donor statin use was associated with an increased incidence of respiratory viral infections in recipients (aHR 2.84 (95% CI 1.3-6.0), P=0.007). The overall incidence of invasive fungal infections and CMV reactivation and CMV disease were not impacted by recipient or donor statin use. In conclusion, this study suggests that recipient or donor statin use may be associated with an increased incidence of some infections without adversely affecting mortality.Bone Marrow Transplantation advance online publication, 19 January 2015; doi:10.1038/bmt.2014.279.
    Bone Marrow Transplantation 01/2015; 50(3). DOI:10.1038/bmt.2014.279 · 3.47 Impact Factor